Kenvue Inc.

NYSE: KVUE·Summit, New Jersey·

Price
$19.31
Base IV
$13.42

Valuation snapshot

Above base case

At $19.31, the price sits between our base case ($13.42) and bull case ($19.60).

Values per share, from an .

No growth
…
Loading earnings power
Base case
$13.42
69% of the price · range $8.01–$19.60
Price vs base case
44% above
$19.31 against $13.42
Base casevalued by DCF
Price vs base
Priceclose 10‑30

Whisker on the base case runs bear $8.01 to bull $19.60. Values per share.

Price against each value

Bear case
$8.01
Price 141% above
No growth
…
—
Base case
$13.42
Price 44% above
Researched byClaude Opus 5.5
Valuation Nov 13, 2026 · Price as of Oct 30, 2026How we got here

What does Kenvue do?

Kenvue sells consumer health and beauty products, such as pain relief, skin care, and oral care items, to help people manage their daily health and hygiene needs.

It brought in $15.5B of sales in the 12 months to Sep 2026.

Industry
Materials
Based in
Summit, New Jersey
Trades on
NYSE as KVUE

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 11¢ was left as profit after every cost, interest and tax. The biggest cost is running the business, 83¢ of every dollar.

  • Running the business83¢
  • Interest and other costs3¢
  • Tax4¢
  • Left as profit11¢
Totals of the four quarters to Sep 2026, from the company's own filings. The split by product is from the latest fiscal year.

Who pays Kenvue, and for what?

Kenvue makes and sells everyday health and personal care products, such as Tylenol, Zyrtec, Neutrogena, Aveeno, Listerine and BAND-AID. It earns money by selling them through stores and online in more than 165 countries. In fiscal 2025 its net sales were $15.1 billion.

Shoppers buy the products, but Kenvue mostly sells to retailers and distributors: its largest customer brought in about 12% of 2025 net sales and its top 10 customers about 41%.

  • Self Care

    42%

    Medicines you can buy without a prescription and similar products for coughs, colds, allergies, pain, digestion, quitting smoking and eye care. Brands include Tylenol, Zyrtec, Motrin, Benadryl and Nicorette.

  • Essential Health

    31%

    Mouth care, baby care, women's health and wound care products. Brands include Listerine, Johnson's, BAND-AID, Desitin, Stayfree and o.b.

  • Skin Health and Beauty

    27%

    Face, body, hair and sun care products built on skin science and recommended by health professionals. Brands include Neutrogena, Aveeno, Lubriderm, OGX, Le Petit Marseillais and Rogaine.

Share of the latest fiscal year's sales, as the company reports it.

Where its work physically happens, beyond headquarters:

  • São José dos Campos plant — São José dos Campos, Brazil. Kenvue identified this 1.4 million-square-foot facility as its largest listed manufacturing site, serving its Skin Health and Beauty and Essential Health segments.
  • Fort Washington plant — Fort Washington, United States. This 800,000-square-foot Self Care facility produces products including Tylenol, Motrin, Zyrtec and Benadryl.
  • Val-de-Reuil plant — Val-de-Reuil, France. Kenvue listed this 790,000-square-foot facility as manufacturing capacity for both Self Care and Skin Health and Beauty.
  • Las Piedras plant — Las Piedras, United States. This 740,000-square-foot Self Care manufacturing facility represents substantial production capacity in Kenvue’s North American network.
  • Lititz plant — Lititz, United States. This 550,000-square-foot facility produces Skin Health and Beauty and Essential Health products, including Listerine, Aveeno and Johnson’s Baby products.
See them on the globe

Kenvue Inc. Form 10-K for fiscal year 2025

How is the business doing?

Sales have barely moved over 3 years, from $15B in 2022 to $15.1B in 2025.

Running the business leaves about 17¢ of each sales dollar as operating profit, about the same as 18¢ in 2022.

After paying for its upkeep and new investment, it had $2.3B of cash to spare in the 12 months to Sep 2026.

Sales$15.1B
20222025
Operating margin16%
20222025
Free cash flow$1.7B
20222025
Each bar is one fiscal year (2022–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

Kenvue says it exists to help people live healthier lives through the small acts of care they repeat every day.

“our purpose is to realize the extraordinary power of everyday care.”

Kenvue Inc. Form 10-K for fiscal year 2025

What management says it is working on now:

  • Completing the Kimberly-Clark deal

    Kenvue agreed to be bought by Kimberly-Clark for cash and shares. Shareholders of both companies approved it in January 2026, and the US competition review waiting period ended in February 2026. Approvals from other countries are still needed.

    Kenvue Inc. Form 10-K for fiscal year 2025
  • Cutting costs to fund its brands

    Through a program called Our Vue Forward, Kenvue is cutting costs and working more efficiently, and putting the savings back into its brands. It says it has largely finished its 2024 restructuring and approved a new one in February 2026.

    Kenvue Inc. Form 10-K for fiscal year 2025
  • Running on its own systems after leaving J&J

    Since splitting from Johnson & Johnson, Kenvue has stopped relying on J&J for services and manufacturing. It has been building and upgrading its own systems, changing how it is organised and strengthening its leadership team.

    Kenvue Inc. Form 10-K for fiscal year 2025
  • Science-backed new products

    About 1,600 scientists, doctors, pharmacists and engineers work with health professionals on new products. One example: in 2026 the US Food and Drug Administration (FDA) approved Tylenol with Naproxen, a non-prescription pill that combines two pain relievers.

    Kenvue Reports Second Quarter 2026 Results (Form 8-K)
  • Digital marketing

    Kenvue calls itself a modern digital marketer. It uses data, online shopping channels, influencers and health professionals to promote its brands, and judges its advertising by the return it brings.

    Kenvue Inc. Form 10-K for fiscal year 2025
Restructuring charges, fiscal 2026
About $250 million before tax
Kenvue Reports Second Quarter 2026 Results (Form 8-K)
Cost savings from combining with Kimberly-Clark, within the first 3 years after the deal closes
About $1.9 billion
Kimberly-Clark to Acquire Kenvue (joint press release)
Extra profit from added sales after combining with Kimberly-Clark, within 4 years after the deal closes
About $500 million, with about $300 million of it put back into the business
Kimberly-Clark to Acquire Kenvue (joint press release)
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is holding steady. In Q3 2026 it sold 3% more than a year earlier. The year before, quarters averaged 2%.

Its operating margin is wider than a year ago: 18¢ per sales dollar, against 17¢.

Recently

Coming up

  • Expected Q4 2026

    Kimberly-Clark deal expected to close

    For each Kenvue share, shareholders would receive 0.14625 Kimberly-Clark shares plus $3.50 in cash. They would own about 46% of the combined company. The deal still needs approvals from other countries.

    Kenvue Reports Second Quarter 2026 Results (Form 8-K)
  • Pending, no date given

    FDA decision on acetaminophen labels

    The FDA has started changing acetaminophen labels about use in pregnancy, and two outside groups have asked it to add warnings. Kenvue has asked the FDA to reject the first request. The final wording could affect Tylenol sales.

    Kenvue Inc. Form 10-K for fiscal year 2025
  • Approved in 2026

    Tylenol with Naproxen launch

    The FDA approved Tylenol with Naproxen, the first non-prescription pill that combines acetaminophen with the pain reliever naproxen sodium. It is a new product for the Self Care segment.

    Kenvue Reports Second Quarter 2026 Results (Form 8-K)
  • During fiscal 2026

    2026 restructuring program

    Kenvue's board approved a new restructuring program in February 2026. The company expects about $250 million in related charges during fiscal 2026.

    Kenvue Reports Second Quarter 2026 Results (Form 8-K)

Our own estimate moved too: the base case went from $18.74 to $13.42 a share between our last two valuations.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. The Kimberly-Clark deal could be delayed, fail or disappoint

    The deal still needs approvals from other countries, and some shareholders have sued. While it is pending, the deal limits what Kenvue can do, costs money and could unsettle staff and partners. Even if it closes, the expected savings may not fully arrive.

    From the company's own filingsWould hit how much of each sale it keepsKenvue Inc. Form 10-K for fiscal year 2025

  2. Safety concerns about Tylenol's main ingredient and other products

    In 2025, US officials suggested that using acetaminophen in pregnancy may be linked to autism, and the FDA began a label change. Kenvue says this may reduce sales and lead to more lawsuits. Concerns about talc and phenylephrine also carry legal risk.

    From the company's own filingsWould hit how fast sales growKenvue Inc. Form 10-K for fiscal year 2025

  3. Strong competitors and powerful retailers

    Kenvue competes with large firms like Procter & Gamble, Haleon and L'Oréal, and with cheaper store brands. A few big retailers make up a large share of its sales, which gives them strong bargaining power over prices and terms.

    From the company's own filingsWould hit how fast sales growKenvue Inc. Form 10-K for fiscal year 2025

  4. Weak growth in skin care

    In 2025 Kenvue lowered its long-term outlook for Skin Health and Beauty because skin care categories are growing slowly and the unit's profits have fallen. It warns that if things get worse, it may have to write down the value of that business.

    From the company's own filingsWould hit how fast sales growKenvue Inc. Form 10-K for fiscal year 2025

  5. Tariffs and higher material costs

    Kenvue estimates that US tariffs and other countries' retaliatory tariffs could cost it about $130 million a year before any steps to reduce the impact. Rising prices for raw materials could also squeeze its profits.

    From the company's own filingsWould hit how much of each sale it keepsKenvue Inc. Form 10-K for fiscal year 2025

  6. Lower sales volumes

    Net sales fell 2.1% in 2025, mainly because Kenvue sold fewer units. US retailers cut how much stock they held, shipment timing in China changed, and allergy, cough, cold and children's pain seasons were milder.

    From the company's own filingsWould hit how fast sales growKenvue Inc. Form 10-K for fiscal year 2025

  7. Kenvue stopped giving forward guidance because of the Kimberly-Clark transaction, so there is no management anchor.

    From our researchWould hit how fast sales growKenvue Q3 2026 earnings release

  8. Q4 GAAP margins were 13.2% in 2024 and 14.2% in 2025, showing that year-end charges pull the full-year margin down.

    From our researchWould hit how much of each sale it keepsKenvue Q3 2026 10-Q

Is it a good business?

From 2022 to 2025 it earned between 8% and 11% on the capital invested in it, a median of 10%. Its cost of capital in the latest valuation is 7.2%; returns were above it in every one of the 4 years.

From 2022 to 2025 it earned between 10% and 15% on its shareholders' equity, a median of 12%.

Over 4 years its operating margin ranged from 12¢ to 18¢ per sales dollar, a median of 16¢. Gross margin ran from 55¢ to 58¢.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on invested capital10%
20222025

Cost of capital 7.2%

Return on equity14%
20222025
Return on invested capital is operating profit after tax (at the median effective rate, 25%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

The number of shares has held roughly steady over the past year.

It owes $7.2B more than it holds in cash, about 2.6 years of operating profit.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $19.31. Our put its value between $8.01 and $19.60, with $13.42 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $8.01

This scenario assumes Kenvue's recent pickup in sales fades back toward the flat-to-shrinking pattern of 2023 to 2025, and that profits stay around today's level instead of improving.

Base case, $13.42

This scenario assumes Kenvue keeps growing sales at roughly the 3% pace of the past year and slowly improves its profitability as one-time restructuring costs fade.

Bull case, $19.60

This scenario assumes Kenvue builds on its best recent quarters, with sales growing around 4% a year and profits rising as cost savings from joining Kimberly-Clark come through.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects more than we do.Price above value: 44%

For Kenvue to be worth today's $19.31, sales would need to grow about 9.6% a year. We assume 2.8%. Over the last 4 years, sales grew 1.0% a year.

−2%0%+2%+4%+6%+8%+10%+12%Past 4 yrs 1.0%We assume 2.8%Price needs 9.6%

Or, if sales grow 2.8% as we assume, the price works with a profit margin of 25.5% (we assume 19.0%).

Keep in mind: this is one way to read the price. Investors might be expecting other things, like higher profits or lower risk.

Do you think sales can grow 9.6% a year?

Try your own numbers

We're moderately sure of this range: it scores 62 out of 100 on our checks. The weakest point is terminal-value dependency.

Test the assumptions

Our base value of $13.42 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average2.8%
  • Operating margin19.0%
  • Long-term growth rate2.2%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$13.42 -30.5%

Build